BHVN Stock: Price, Earnings History and SEC Filings
Biohaven Ltd. (BHVN) last traded at $15.42, down 6.49% on the latest session and up 15.5% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-0.86 against an analyst estimate of $-0.80, a miss of 7.5%.
$15.42 -6.49%
1 month+15.51%
52-week high$18.24
52-week low$7.48
Volume3.16M
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BHVN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $-0.86 | $-0.80 | -7.50% |
| Jun 2026 | Aug 10, 2026 | $-0.91 | $-0.77 | -18.18% |
| Mar 2026 | May 4, 2026 | $-0.88 | $-0.86 | -2.33% |
| Dec 2025 | Mar 2, 2026 | $-1.21 | $-1.22 | +0.82% |
BHVN beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
BHVN financial history
Net income
Free cash flow
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$739M | -$610M | – | $-6.86 |
| 2024 | – | -$846M | -$587M | – | $-9.28 |
| 2023 | – | -$408M | -$335M | – | $-5.73 |
| 2022 | – | -$570M | -$304M | – | $-12.75 |
| 2021 | – | -$214M | -$147M | – | $-5.43 |
| 2020 | – | -$119M | -$77M | – | $-3.01 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BHVN
SEC filing data is not available right now. You can search for BHVN on SEC EDGAR.
BHVN news
- Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data?Oct 30, 2026 · finance.yahoo.com
- Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial ResultsOct 29, 2026 · finance.yahoo.com
- Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to TradeOct 29, 2026 · finance.yahoo.com
- JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsightOct 26, 2026 · finance.yahoo.com
- Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous NephropathyOct 26, 2026 · finance.yahoo.com
- Biohaven Could Transform With Troriluzole's FDA Approval, RBC SaysOct 23, 2026 · finance.yahoo.com
- Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review AcceptanceOct 23, 2026 · finance.yahoo.com
- Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target UpgradeOct 23, 2026 · finance.yahoo.com
About Biohaven Ltd.
Biohaven Ltd. (BHVN) is a US-listed public company on NYSE.